<DOC>
	<DOCNO>NCT02950207</DOCNO>
	<brief_summary>Mono-centric , observational , prospective study , design pt diagnosis hormone-positive breast cancer evaluate correlation response hormonal treatment indicate reduction level Ki67 miRNA100 two group patient</brief_summary>
	<brief_title>Prospective Observational Study Antitumor Activity Correlation Between Hormonal Therapy Expression miRNA100</brief_title>
	<detailed_description>The potential role miRNAs study predictor hormone sensitivity hormone-positive breast carcinoma . The miRNA100 obtain biopsy compare expression level obtain surgically removed tumor , order ass possible modulation miRNA100 follow hormonal treatment .</detailed_description>
	<criteria>Ability provide write informed consent Age great 18 year histological diagnosis invasive carcinoma breast Xray evidence ( mammography / ultrasound ) strongly suggestive presence invasive breast cancer ( BIRADS 4c BIRADS 5 ) great 15mm diameter . Carcinoma stage I ( diameter &gt; 15 mm ) II , unresectable , Carcinoma stage II III , operable result presurgical therapy , Carcinoma IV debut stage , asymptomatic , primary operable breast cancer , result presurgical therapy Positivity estrogen receptor / progestin define expression one hormone receptor â‰¥10 % tumor cell Negativity HER2 Cell proliferation , define percentage Ki67 positive tumor cell , &gt; 5 % ( correspond value 1.79 lognormal transformation ) Postmenopausal status Ability take oral therapy , absence malabsorption syndrome know , previous stomach surgery small intestine Ability perform stag examination screen provide Protocol Eastern Cooperative Oncology Group ( ECOG ) = 0 The patient normal bone marrow function , liver kidney Previous treatment breast cancer chemotherapy , lapatinib , trastuzumab , letrozole , anastrozole , exemestane tamoxifen . Other cancer diagnose last five year , exception basal cell squamous cell carcinoma skin , melanoma situ cervical cancer situ . Premenopausal Known hypersensitivity letrozole excipients ( example : woman rare hereditary problem galactose intolerance , Lapp lactase deficiency mal absorption glucose / galactose ) . Evidence severe poorly control systemic disease affect lung , heart , liver , kidney may compromise adherence treatment extend followup . Inflammatory bowel disease control ( eg Crohn 's disease , ulcerative colitis ) . Active infection / inadequately control . Alteration mental status , dementia , psychiatric condition might impair ability consciously sign informed consent . Breast cancer triple negative , negative HER2 overexpression expression hormone receptor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>